|

Iruplinalkib tablets Clinical Trials

2 actively recruiting trials

Also known as: Qi Xin Ke

Pipeline

Early 1: 1

Top Sponsors

  • Peking University Shenzhen Hospital1
  • Henan Cancer Hospital1

Indications

  • Lung Cancer2
  • Non Small Cell Lung Cancer2
  • Cancer2
  • Lorlatinib1
  • Iruplinalkib1

Other2 trials

An Exploratory Study of Efficacy and Safety of Iruplinalkib Tablets in Patients With ROS1 Positive Non-small Cell Lung Cancer
Early 1
Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.